Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Forte

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.
Frontiers in Pharmacology|January 18, 2024
Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor <i>in vivo</i> acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncologyIméne Ben Toumia, Tiziana Bachetti, Leila Chekir-Ghedira, et al.
Molecular Cancer|June 10, 2008
Involvement of GTA protein NC2beta in neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferationCinzia Di Pietro, Marco Ragusa, Davide Barbagallo, et al.
Carcinogenesis|June 25, 2015
Disruptive chemicals, senescence and immortalityAmancio Carnero, Carmen Blanco-Aparicio, Hiroshi Kondoh, et al.
Carcinogenesis|May 24, 2015
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsJulia Kravchenko, Emanuela Corsini, Marc A Williams, et al.
Carcinogenesis|June 25, 2015
Environmental immune disruptors, inflammation and cancer riskPatricia A Thompson, Mahin Khatami, Carolyn J Baglole, et al.
Carcinogenesis|June 25, 2015
Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?R Brooks Robey, Judith Weisz, Nancy B Kuemmerle, et al.
Carcinogenesis|June 25, 2015
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingWilhelm Engström, Philippa Darbre, Staffan Eriksson, et al.
Carcinogenesis|June 25, 2015
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisZhiwei Hu, Samira A Brooks, Valérian Dormoy, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.
Frontiers in Pharmacology|January 18, 2024
Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor <i>in vivo</i> acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncologyIméne Ben Toumia, Tiziana Bachetti, Leila Chekir-Ghedira, et al.
Molecular Cancer|June 10, 2008
Involvement of GTA protein NC2beta in neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferationCinzia Di Pietro, Marco Ragusa, Davide Barbagallo, et al.
Carcinogenesis|June 25, 2015
Disruptive chemicals, senescence and immortalityAmancio Carnero, Carmen Blanco-Aparicio, Hiroshi Kondoh, et al.
Carcinogenesis|May 24, 2015
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsJulia Kravchenko, Emanuela Corsini, Marc A Williams, et al.
Carcinogenesis|June 25, 2015
Environmental immune disruptors, inflammation and cancer riskPatricia A Thompson, Mahin Khatami, Carolyn J Baglole, et al.
Carcinogenesis|June 25, 2015
Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?R Brooks Robey, Judith Weisz, Nancy B Kuemmerle, et al.
Carcinogenesis|June 25, 2015
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingWilhelm Engström, Philippa Darbre, Staffan Eriksson, et al.
Carcinogenesis|June 25, 2015
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisZhiwei Hu, Samira A Brooks, Valérian Dormoy, et al.
Pageof 10